Description: This session from the 1984 SOA Toronto Meeting discusses an overview of the underwriting methods and techniques used with individually issued accident and health insurance including elimination periods, underwriting limits and claims costs. From Record of the Society of Actuaries Vol. 10, No. 4

Description: This article is from the Digest of Informal Discussion, Transactions of Society of Actuaries 1956 Volume 8, Number 20. The discussion identifies the participants and summarizes each person’s comments. The participants discuss: records and accounting of the varied types of Group Accident and Sickness coverage practices of group insurance policyholders with respect to the continuation of coverage on their retired employees, for life and other group coverages and with respect to small [under 50 lives] groups, types of benefits available, and underwriting, administrative, and marketing issues.

Description: This article is part of the Digest of Informal Discussion, which took place at the 1955 Society of Actuaries Eastern Spring Meeting, held March 24-25 in New York City. The article identifies the participants and summarizes each person’s comments. The participants discuss problems related to submitting data to the Committee on Experience under Individual Accident and Sickness Insurance, policy changes involving an increase in benefits insured, use of the ratio of actual to expected claims vs. the ratio of claims to premiums, and group valuation methods. From Transactions of Society of Actuaries 1955 Volume 7, Number 18.

Description: This article is part of the Digest of Informal Discussion, which took place at the 1956 Society of Actuaries Eastern Spring Meeting, held April 19-20 in Hartford, CT. It identifies the participants and summarizes each person’s comments. The participants discuss progress made in offering accident and sickness and hospitalization insurance benefits to those over 65, the physically impaired, to rural areas, and to lower income groups, and discuss methods to further extend benefits to those groups. They also discuss experience with major medical policies, and what insurance associations such as the Health Insurance Association of America, can do to collect morbidity data. From Transactions of Society of Actuaries 1956 Volume 8, Number 21.

Description: Offering supplemental benefits likes accident, hospital indemnity and critical illness to traditional worksite employees has become routine, but how do you handle gig workers? Traditionally these workers would be considered uninsurable, but can you afford to ignore them? The panel will discuss the unique factors of the gig economies and key thoughts for providing insurance in this space.

Description: In this session, the panelists describe the types of accident products currently being marketed and discuss a variety of issues related to product design, underwriting, and marketing. From the 2002 Record of Society of Actuaries, Volume 28, No. 3. Session 120PD of the Boston Annual Meeting.

Description: Stale portfolio got your sales down? In this session, you'll learn about the latest and greatest in product development trends and innovations which you can use to refresh and revitalize your products. At the conclusion of this session, attendees will have a better understanding on market trends in product development as well as leading innovations.

Description: This discussion focuses on Group Accident and Health Insurance, particularly, is there a solution to continually revising rates, what are the advantages and disadvantages of rates that vary by area, and on what size cases is the loss ratio with the previous carrier sought? From Transactions of Society 1960, Vol. 12, No. 33.

Description: Summary of research from the Initiative 18/11 - Pharmacy team about the drug development process for traditional pharmaceuticals: Who does the research and discovery? What does the research and discovery process entail? How are targets identified and validated for research and discovery? What are clinical trials and how are they conducted? How is the drug development process regulated? How is the drug development process funded?